contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


gubra-afslutter-2024-med-endnu-et-staerkt-ar-i-cro-og-gode-data-i-dandp

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Equity Research Analyst

Philip Coombes

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.

Gubra

Gubra: Afslutter 2024 med endnu et stærkt år i CRO og gode data i D&P

Aktien lukkede i 644 torsdag og er op med 3% YTD.
CRO: Oms&#xe6;tningen er op med 31% i 2024 sammenlignet med guidance i starten af &#xe5;ret p&#xe5; 10-15% og seneste udmelding om 26-28%. V&#xe6;ksten er drevet af &quot;Obesity&quot; hvor Gubra er markedsledende indenfor high-end pr&#xe6;klinisk service, derudover er v&#xe6;ksten drevet af &quot;Kidney&quot; hvor selskabet har opbygget sin position over de seneste &#xe5;r. L&#xf8;nsomheden m&#xe5;lt p&#xe5; ebit-margin kommer ind p&#xe5; 30% vs 27% i 2023 og i overenstemmelse med guidance.
D&amp;P: Selskabet offentliggjorde data fra sit Fase 1a i GUBamy SAD(Single Ascending Dose) studiet i november 2024 med en rigtig god tolerance og insignifikante bivirkninger GI-relateret.
Highlights 2024:
<img src="https://content.inderes.se/assets/0ad9c97c-cc33-4cb0-abd6-ca59bc7cc25c?width=649&amp;height=407" alt="Gubra 2024">
Gubra 2025 Guidance:
<img src="https://content.inderes.se/assets/badca4fa-d453-4a00-82be-ab929c610bf3?width=686&amp;height=212" alt="Gubra 2025 Guidance">
Grundet den h&#xf8;je v&#xe6;kst i CRO forretningen de seneste to &#xe5;r med 69% og det &#xf8;get pres p&#xe5; teknologiplatformen, guider selskabet nu 10-20% oms&#xe6;tningsv&#xe6;kst i CRO. Det vil nu fokusere platformen mere mod D&amp;P divisionen, de &#xf8;nsker at bringe flere projekter i klinisk fase samt udvide antal omr&#xe5;de til ogs&#xe5; at omfatte Women&apos;s Health.
Vi afholder i dag event med Gubra kl 13:00 - tilmeld dig her: <a href="https://www.inderes.dk/videos/gubra-praesentation-af-arsregnskabet-2024" target="_blank" rel="noopener">Gubra event</a>
Disclaimer: HC Andersen Capital modtager betaling fra Gubra p&#xe5; en Digital IR/Corporate Visibility aftale./Claus Thestrup 28.02.2025 kl 09:00.